查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1980186

中樞神經系統療法市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類的洞察，2026-2034 年預測

Central Nervous System Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 請詢問到貨日

價格

中樞神經系統（CNS）治療市場成長要素

2025年全球中樞神經系統（CNS）治療市場規模為1,266.8億美元，預計2026年將成長至1,386.6億美元，到2034年將達2,369.4億美元，2026年至2034年的年複合成長率（CAGR）為6.93%。2025年，北美市場佔據主導地位，佔全球市場佔有率的45.70%。這得益於北美健全的法規結構、較高的治療可及性以及主要企業的存在。

中樞神經系統（CNS）治療市場涵蓋神經退化性疾病、神經血管疾病、精神疾病和感染性神經系統疾病的治療方法。阿茲海默症、帕金森氏症、癲癇和多發性硬化症等神經系統疾病的日益普遍，顯著地推動了市場擴張。

新冠疫情的影響

新冠疫情對中樞神經系統（CNS）治療市場造成了負面影響，導致2024年市場規模下降4.2%。製藥公司將研發重點轉向新冠疫苗和治療藥物，2024年銷售額將減少1,158.4億美元。然而，隨著需求恢復到疫情前水準以及藥物研發活動的重啟，市場在2025年得以復甦。

市場促進因素

神經系統疾病盛行率增加

全球神經系統疾病負擔日益加重是成長要素。在美國，約有600萬人患有阿茲海默症，預計未來幾十年這一數字將顯著增加。每年的治療和護理費用超過3050億美元，因此對有效的中樞神經系統療法有著強烈的需求。

此外，多發性硬化症、帕金森氏症、癲癇和精神疾病的病例數量不斷增加，患者群體日益擴大。全球人口老化進一步加速了對先進治療方法的需求。

有前景的在研藥物

多款處於後期臨床試驗階段的創新分子和生物製藥可望提振市場前景。製藥公司之間的策略聯盟和授權協議提高藥物研發效率，並擴大全球商業化機會。

市場限制因素

儘管中樞神經系統（CNS）治療市場具有成長前景，但也面臨許多挑戰：

  • 嚴格的監管核准
  • 高昂的研發成本
  • 臨床開發週期越來越長。
  • 穿過血腦障壁的難度
  • 關於藥物不良反應和安全性的警告

例如，2025年，美國食品藥物管理局（FDA）發布了一項關於某些多發性硬化症藥物的安全警告，指出其使用可能存在風險。這些因素可能會在預測期內限制市場成長。

市場區隔分析

依疾病類型

  • 到2026年，神經退化性疾病將引領市場，佔據 47.08%的市場佔有率，這主要得益於多發性硬化症和阿茲海默症治療藥物的銷售成長。
  • 由於全球意識的提高以及後疫情時代人們所經歷的心理壓力，對心理健康服務的需求增加。
  • 神經血管疾病和感染疾病也是推動市場穩定成長的因素。

藥物類別

  • 到2026年，免疫調節藥物將以 52.08%的市場佔有率引領市場，這得益於多發性硬化症治療領域的創新。
  • 干擾素、抗憂鬱症、多巴胺促效劑、鎮痛藥和其他中樞神經系統（CNS）藥物對總銷售額貢獻巨大。

依藥物類型

  • 到2026年，非生物製藥將佔據市場主導地位，市場佔有率達 69.05%，這得益於其易於獲得監管部門核准和較高的處方率。
  • 在政府支持措施和生物製藥產品線不斷擴大的推動下，生物製藥產業有望穩步成長。

依通路

  • 由於處方藥銷量高以及人們更傾向於住院治療，醫院藥房佔據了最大的市場佔有率。
  • 零售藥局和網路藥局擴張，尤其是在新興市場。

區域趨勢

北美洲

預計到2025年，北美市場規模將達到579.6億美元，到2026年將達到631.3億美元。光是美國市場預計到2026年就將達到582.5億美元。該成長得益於強大的研發基礎設施、高疾病盛行率、FDA的監管支持以及健全的償付體系。

歐洲

歐洲佔據第二大市場佔有率，這得益於其優惠的償付政策和公共醫療保健體系，例如英國國家醫療服務體系（NHS）。預計到2026年，英國市場規模將達到49.8億美元，德國市場規模預計將達到75.1億美元。

亞太地區

由於老齡人口不斷成長以及醫療基礎設施的不斷完善，亞太地區預計將成為年複合成長率最高的地區。到2026年，日本市場預計將達到90.4億美元，中國59.9億美元，印度31.6億美元。

拉丁美洲、中東和非洲

由於產品核准數量有限且市場滲透速度緩慢，預計這些地區的成長將較為溫和。

主要企業

中樞神經系統（CNS）治療市場的主要企業包括以下幾家：

  • Biogen
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Otsuka Holdings

這些公司正致力於擴大產品線、建立合作夥伴關係、核准監管機構批准以及擴大營運區域，以鞏固其市場地位。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會

第4章 主要考察

  • 產業重大發展動態 - 併購與合作
  • 新產品發布
  • 管道分析
  • 監理情勢概述
  • 新冠疫情對市場的影響

第5章 全球中樞神經系統治療市場分析、洞察與預測（2025-2034年）

  • 主要發現與總結
  • 市場分析、洞察與預測：依藥物類別分類
    • 免疫調節藥物
    • 干擾素
    • 脫羧酶抑制劑
    • 多巴胺促效劑
    • 抗憂鬱症
    • 止痛藥
    • 其他
  • 市場分析、洞察與預測：依疾病類型分類
    • 神經血管疾病
      • 出血性中風
      • 缺血性中風
      • 其他
    • 神經退化性疾病
      • 阿茲海默症
      • 帕金森氏症
      • 多發性硬化症
      • 其他
    • 心理健康
      • 癲癇
      • 情緒障礙
      • 焦慮症
      • 其他
      • 感染疾病
      • 腦膜炎
      • 腦炎
      • 其他
    • 其他
  • 市場分析、洞察與預測：依通路分類
    • 醫院藥房
    • 零售藥房
    • 其他
  • 市場分析、洞察與預測：依藥物類型分類
    • 生物製藥
    • 非生物製藥
  • 市場分析、洞察與預測：依地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美中樞神經系統療法市場分析、洞察與預測（2025-2034年）

  • 國家
    • 美國（依藥物類型）
    • 加拿大（依藥物類型）

第7章 歐洲中樞神經系統治療市場分析、洞察與預測（2025-2034年）

  • 國家
    • 英國（依藥物類型）
    • 德國（依藥物類型）
    • 法國（依藥物類型）
    • 西班牙（依藥物類型）
    • 義大利（依藥物類型）
    • 斯堪地那維亞（依藥物類型）
    • 其他歐洲國家（依藥物類型）

第8章 亞太地區中樞神經系統治療市場分析、洞察與預測（2025-2034年）

  • 國家
    • 日本（依藥物類型）
    • 中國（依藥品類型）
    • 印度（依藥物類型）
    • 澳洲（依藥物類型）
    • 東南亞（依藥物類型）
    • 其他亞太地區（依藥物類型）

第9章 拉丁美洲中樞神經系統治療市場分析、洞察與預測（2025-2034年）

  • 國家
    • 巴西（依藥物類型）
    • 墨西哥（依藥物類型）
    • 其他拉丁美洲國家（依藥物類型）

第10章 中東和非洲中樞神經系統治療市場分析、洞察與預測（2025-2034年）

  • 國家
    • 海灣合作理事會國家（依藥物類型）
    • 南非（依藥物類型）
    • 其他中東和非洲地區（依藥物類型）

第11章 競爭分析

  • 主要行業趨勢
  • 全球市場佔有率分析（2025年）
  • 公司簡介
    • Biogen
    • Pfizer, Inc.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Johnson and Johnson Services Inc.
    • Teva Pharmaceutical Industries Lt
    • Sanofi
    • Otsuka Holdings
    • Other Prominent Players
Product Code: FBI103973

Growth Factors of central nervous system (CNS) treatment Market

The global central nervous system (CNS) treatment market was valued at USD 126.68 billion in 2025 and is projected to grow to USD 138.66 billion in 2026, reaching USD 236.94 billion by 2034, registering a CAGR of 6.93% during 2026-2034. North America dominated the market in 2025, accounting for 45.70% of the global share, supported by strong regulatory frameworks, high treatment accessibility, and the presence of leading pharmaceutical companies.

The CNS treatment market includes therapies for neurodegenerative diseases, neurovascular disorders, mental health conditions, infectious neurological diseases, and others. Rising prevalence of neurological disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis is significantly contributing to market expansion.

COVID-19 Impact

The COVID-19 pandemic had a negative impact on the CNS treatment market, resulting in a -4.2% decline in 2024. Pharmaceutical companies shifted their R&D focus toward COVID-19 vaccines and therapeutics, causing an estimated USD 115.84 billion sales drop in 2024. However, the market rebounded in 2025 as demand returned to pre-pandemic levels and drug development activities resumed.

Market Drivers

Growing Prevalence of Neurological Disorders

The increasing global burden of neurological diseases is a primary growth driver. In the U.S., around 6 million people live with Alzheimer's disease, and this number is projected to rise significantly in the coming decades. The annual treatment and care costs exceed USD 305 billion, creating strong demand for effective CNS therapeutics.

Additionally, rising cases of multiple sclerosis, Parkinson's disease, epilepsy, and mental health disorders are expanding the patient pool. Growing geriatric populations worldwide further accelerate demand for advanced treatment options.

Promising Pipeline Drugs

Several innovative molecules and biologics in late-stage clinical trials are expected to strengthen the market outlook. Strategic collaborations and licensing agreements between pharmaceutical companies are increasing drug development efficiency and global commercialization opportunities.

Market Restraints

Despite growth prospects, the CNS treatment market faces notable challenges:

  • Stringent regulatory approvals
  • High R&D costs
  • Long clinical development timelines
  • Difficulty in crossing the blood-brain barrier
  • Adverse drug reactions and safety warnings

For example, in 2025, the U.S. FDA issued safety warnings regarding certain multiple sclerosis drugs, highlighting potential treatment risks. These factors may limit market growth during the forecast period.

Market Segmentation Analysis

By Disease Type

  • Neurodegenerative diseases dominated the market with a 47.08% share in 2026, driven by high sales of multiple sclerosis and Alzheimer's drugs.
  • Mental health disorders are witnessing rising demand due to increased global awareness and post-pandemic psychological stress.
  • Neurovascular and infectious diseases also contribute to steady market growth.

By Drug Class

  • Immunomodulators led the market in 2026 with a 52.08% share, supported by innovation in multiple sclerosis therapies.
  • Interferons, antidepressants, dopamine agonists, analgesics, and other CNS drugs contribute significantly to overall revenue.

By Drug Type

  • Non-biologics dominated the market with a 69.05% share in 2026, owing to easier regulatory approvals and strong prescription rates.
  • Biologics are expected to grow steadily due to supportive government initiatives and expanding biologic pipelines.

By Distribution Channel

  • Hospital pharmacies held the largest share due to high prescription drug sales and preference for hospital-based treatments.
  • Retail pharmacies and online pharmacies are expanding, particularly in emerging markets.

Regional Insights

North America

North America generated USD 57.96 billion in 2025 and USD 63.13 billion in 2026. The U.S. market alone is projected to reach USD 58.25 billion in 2026. Growth is driven by strong R&D infrastructure, high disease prevalence, regulatory support from the FDA, and robust reimbursement systems.

Europe

Europe holds the second-largest market share, supported by favorable reimbursement policies and public healthcare systems such as the NHS. The UK market is projected to reach USD 4.98 billion in 2026, while Germany is projected at USD 7.51 billion in 2026.

Asia Pacific

Asia Pacific is expected to register the highest CAGR due to increasing geriatric populations and improving healthcare infrastructure. The Japan market is projected to reach USD 9.04 billion in 2026, China USD 5.99 billion, and India USD 3.16 billion.

Latin America & Middle East & Africa

These regions are expected to witness moderate growth due to limited product approvals and slower market penetration.

Key Industry Players

Major companies operating in the CNS treatment market include:

  • Biogen
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Johnson & Johnson Services, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Otsuka Holdings

These companies focus on pipeline expansion, partnerships, regulatory approvals, and geographic expansion to strengthen their market positions.

Conclusion

The global CNS treatment market is poised for steady expansion from USD 126.68 billion in 2025 to USD 236.94 billion by 2034, driven by rising neurological disease prevalence, increasing geriatric population, strong R&D pipelines, and improved treatment accessibility. Although regulatory complexities and high development costs present challenges, continued innovation, strategic partnerships, and expanding healthcare infrastructure are expected to sustain long-term market growth across major regions.

Segmentation By Disease Type

  • Neurovascular Diseases
    • Hemorrhagic Stroke
    • Ischemic Stroke
    • Others
  • Neurodegenerative Diseases
    • Alzheimer's Disease
    • Parkinson's Disease
    • Multiple Sclerosis
    • Others
  • Mental Health
    • Epilepsy
    • Mood Disorders
    • Anxiety Disorders
    • Others
  • Infectious Diseases
    • Meningitis
    • Encephalitis
    • Others
  • Others

By Drug Class

  • Immunomodulatory Drugs
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Antidepressants
  • Analgesics
  • Others

By Drug Type

  • Biologics
  • Non-biologics

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Disease Type, By Drug Class, By Drug Type By Distribution Channel, and By Country)
    • U.S. (By Drug Type)
    • Canada (By Drug Type)
  • Europe (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and By Country)
    • U.K. (By Drug Type)
    • Germany (By Drug Type)
    • France (By Drug Type)
    • Italy (By Drug Type)
    • Spain (By Drug Type)
    • Rest of Europe (By Drug Type)
  • Asia Pacific (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and By Country)
    • China (By Drug Type)
    • Japan (By Drug Type)
    • India (By Drug Type)
    • Australia (By Drug Type)
    • Southeast Asia (By Drug Type)
    • Rest of Asia Pacific (By Drug Type)
  • Latin America (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and by Country)
    • Brazil (By Drug Type)
    • Mexico (By Drug Type)
    • Rest of Latin America (By Drug Type)
  • Middle East & Africa (By Disease Type, By Drug Class, By Drug Type, By Distribution Channel, and by Country)
    • GCC (By Drug Type)
    • South Africa (By Drug Type)
    • Rest of Middle East & Africa (By Drug Type)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Key Industry Developments- Mergers, Acquisitions and Partnerships
  • 4.2. New Product Launches
  • 4.3. Pipeline Analysis
  • 4.4. Overview of Regulatory Scenario
  • 4.5. Impact of COVID-19 on the Market

5. Global Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Drug Class
    • 5.2.1. Immunomodulatory Drugs
    • 5.2.2. Interferons
    • 5.2.3. Decarboxylase Inhibitors
    • 5.2.4. Dopamine Agonists
    • 5.2.5. Antidepressants
    • 5.2.6. Analgesics
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Disease Type
    • 5.3.1. Neurovascular Diseases
      • 5.3.1.1. Hemorrhagic Stroke
      • 5.3.1.2. Ischemic Stroke
      • 5.3.1.3. Others
    • 5.3.2. Neurodegenerative Diseases
      • 5.3.2.1. Alzheimer's Disease
      • 5.3.2.2. Parkinson's Disease
      • 5.3.2.3. Multiple Sclerosis
      • 5.3.2.4. Others
    • 5.3.3. Mental Health
      • 5.3.3.1. Epilepsy
      • 5.3.3.2. Mood Disorders
      • 5.3.3.3. Anxiety Disorders
      • 5.3.3.4. Others
      • 5.3.3.5. Infectious Diseases
      • 5.3.3.6. Meningitis
      • 5.3.3.7. Encephalitis
      • 5.3.3.8. Others
    • 5.3.4. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Drug Type
    • 5.5.1. Biologics
    • 5.5.2. Non-biologics
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis, Insights and Forecast - By Drug Class
    • 6.2.1. Immunomodulatory Drugs
    • 6.2.2. Interferons
    • 6.2.3. Decarboxylase Inhibitors
    • 6.2.4. Dopamine Agonists
    • 6.2.5. Antidepressants
    • 6.2.6. Analgesics
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Disease Type
    • 6.3.1. Neurovascular Diseases
      • 6.3.1.1. Hemorrhagic Stroke
      • 6.3.1.2. Ischemic Stroke
      • 6.3.1.3. Others
    • 6.3.2. Neurodegenerative Diseases
      • 6.3.2.1. Alzheimer's Disease
      • 6.3.2.2. Parkinson's Disease
      • 6.3.2.3. Multiple Sclerosis
      • 6.3.2.4. Others
    • 6.3.3. Mental Health
      • 6.3.3.1. Epilepsy
      • 6.3.3.2. Mood Disorders
      • 6.3.3.3. Anxiety Disorders
      • 6.3.3.4. Others
      • 6.3.3.5. Infectious Diseases
      • 6.3.3.6. Meningitis
      • 6.3.3.7. Encephalitis
      • 6.3.3.8. Others
    • 6.3.4. Others
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Drug Type
    • 6.5.1. Biologics
    • 6.5.2. Non-biologics
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S. (By Drug Type)
    • 6.6.2. Canada (By Drug Type)

7. Europe Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis, Insights and Forecast - By Drug Class
    • 7.2.1. Immunomodulatory Drugs
    • 7.2.2. Interferons
    • 7.2.3. Decarboxylase Inhibitors
    • 7.2.4. Dopamine Agonists
    • 7.2.5. Antidepressants
    • 7.2.6. Analgesics
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Disease Type
    • 7.3.1. Neurovascular Diseases
      • 7.3.1.1. Hemorrhagic Stroke
      • 7.3.1.2. Ischemic Stroke
      • 7.3.1.3. Others
    • 7.3.2. Neurodegenerative Diseases
      • 7.3.2.1. Alzheimer's Disease
      • 7.3.2.2. Parkinson's Disease
      • 7.3.2.3. Multiple Sclerosis
      • 7.3.2.4. Others
    • 7.3.3. Mental Health
      • 7.3.3.1. Epilepsy
      • 7.3.3.2. Mood Disorders
      • 7.3.3.3. Anxiety Disorders
      • 7.3.3.4. Others
      • 7.3.3.5. Infectious Diseases
      • 7.3.3.6. Meningitis
      • 7.3.3.7. Encephalitis
      • 7.3.3.8. Others
    • 7.3.4. Others
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Drug Type
    • 7.5.1. Biologics
    • 7.5.2. Non-biologics
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.6.1. U.K. (By Drug Type)
    • 7.6.2. Germany (By Drug Type)
    • 7.6.3. France (By Drug Type)
    • 7.6.4. Spain (By Drug Type)
    • 7.6.5. Italy (By Drug Type)
    • 7.6.6. Scandinavia (By Drug Type)
    • 7.6.7. Rest of Europe (By Drug Type)

8. Asia Pacific Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis, Insights and Forecast - By Drug Class
    • 8.2.1. Immunomodulatory Drugs
    • 8.2.2. Interferons
    • 8.2.3. Decarboxylase Inhibitors
    • 8.2.4. Dopamine Agonists
    • 8.2.5. Antidepressants
    • 8.2.6. Analgesics
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Disease Type
    • 8.3.1. Neurovascular Diseases
      • 8.3.1.1. Hemorrhagic Stroke
      • 8.3.1.2. Ischemic Stroke
      • 8.3.1.3. Others
    • 8.3.2. Neurodegenerative Diseases
      • 8.3.2.1. Alzheimer's Disease
      • 8.3.2.2. Parkinson's Disease
      • 8.3.2.3. Multiple Sclerosis
      • 8.3.2.4. Others
    • 8.3.3. Mental Health
      • 8.3.3.1. Epilepsy
      • 8.3.3.2. Mood Disorders
      • 8.3.3.3. Anxiety Disorders
      • 8.3.3.4. Others
      • 8.3.3.5. Infectious Diseases
      • 8.3.3.6. Meningitis
      • 8.3.3.7. Encephalitis
      • 8.3.3.8. Others
    • 8.3.4. Others
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Drug Type
    • 8.5.1. Biologics
    • 8.5.2. Non-biologics
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.6.1. Japan (By Drug Type)
    • 8.6.2. China (By Drug Type)
    • 8.6.3. India (By Drug Type)
    • 8.6.4. Australia (By Drug Type)
    • 8.6.5. Southeast Asia (By Drug Type)
    • 8.6.6. Rest of Asia Pacific (By Drug Type)

9. Latin America Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis, Insights and Forecast - By Drug Class
    • 9.2.1. Immunomodulatory Drugs
    • 9.2.2. Interferons
    • 9.2.3. Decarboxylase Inhibitors
    • 9.2.4. Dopamine Agonists
    • 9.2.5. Antidepressants
    • 9.2.6. Analgesics
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Disease Type
    • 9.3.1. Neurovascular Diseases
      • 9.3.1.1. Hemorrhagic Stroke
      • 9.3.1.2. Ischemic Stroke
      • 9.3.1.3. Others
    • 9.3.2. Neurodegenerative Diseases
      • 9.3.2.1. Alzheimer's Disease
      • 9.3.2.2. Parkinson's Disease
      • 9.3.2.3. Multiple Sclerosis
      • 9.3.2.4. Others
    • 9.3.3. Mental Health
      • 9.3.3.1. Epilepsy
      • 9.3.3.2. Mood Disorders
      • 9.3.3.3. Anxiety Disorders
      • 9.3.3.4. Others
      • 9.3.3.5. Infectious Diseases
      • 9.3.3.6. Meningitis
      • 9.3.3.7. Encephalitis
      • 9.3.3.8. Others
    • 9.3.4. Others
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Drug Type
    • 9.5.1. Biologics
    • 9.5.2. Non-biologics
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.6.1. Brazil (By Drug Type)
    • 9.6.2. Mexico (By Drug Type)
    • 9.6.3. Rest of Latin America (By Drug Type)

10. Middle East & Africa Central Nervous System Treatment Market Analysis, Insights and Forecast, 2025-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis, Insights and Forecast - By Drug Class
    • 10.2.1. Immunomodulatory Drugs
    • 10.2.2. Interferons
    • 10.2.3. Decarboxylase Inhibitors
    • 10.2.4. Dopamine Agonists
    • 10.2.5. Antidepressants
    • 10.2.6. Analgesics
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Disease Type
    • 10.3.1. Neurovascular Diseases
      • 10.3.1.1. Hemorrhagic Stroke
      • 10.3.1.2. Ischemic Stroke
      • 10.3.1.3. Others
    • 10.3.2. Neurodegenerative Diseases
      • 10.3.2.1. Alzheimer's Disease
      • 10.3.2.2. Parkinson's Disease
      • 10.3.2.3. Multiple Sclerosis
      • 10.3.2.4. Others
    • 10.3.3. Mental Health
      • 10.3.3.1. Epilepsy
      • 10.3.3.2. Mood Disorders
      • 10.3.3.3. Anxiety Disorders
      • 10.3.3.4. Others
      • 10.3.3.5. Infectious Diseases
      • 10.3.3.6. Meningitis
      • 10.3.3.7. Encephalitis
      • 10.3.3.8. Others
    • 10.3.4. Others
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Drug Type
    • 10.5.1. Biologics
    • 10.5.2. Non-biologics
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.6.1. GCC Countries (By Drug Type)
    • 10.6.2. South Africa (By Drug Type)
    • 10.6.3. Rest of Middle East & Africa (By Drug Type)

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.3.1. Biogen
      • 11.3.1.1. Overview,
      • 11.3.1.2. Products,
      • 11.3.1.3. SWOT analysis,
      • 11.3.1.4. Recent developments,
      • 11.3.1.5. strategies,
      • 11.3.1.6. financials (based on availability)
    • 11.3.2. Pfizer, Inc.
      • 11.3.2.1. Overview,
      • 11.3.2.2. Products,
      • 11.3.2.3. SWOT analysis,
      • 11.3.2.4. Recent developments,
      • 11.3.2.5. strategies,
      • 11.3.2.6. financials (based on availability)
    • 11.3.3. F. Hoffmann-La Roche Ltd
      • 11.3.3.1. Overview,
      • 11.3.3.2. Products,
      • 11.3.3.3. SWOT analysis,
      • 11.3.3.4. Recent developments,
      • 11.3.3.5. strategies,
      • 11.3.3.6. financials (based on availability)
    • 11.3.4. Novartis AG
      • 11.3.4.1. Overview,
      • 11.3.4.2. Products,
      • 11.3.4.3. SWOT analysis,
      • 11.3.4.4. Recent developments,
      • 11.3.4.5. strategies,
      • 11.3.4.6. financials (based on availability)
    • 11.3.5. Johnson and Johnson Services Inc.
      • 11.3.5.1. Overview,
      • 11.3.5.2. Products,
      • 11.3.5.3. SWOT analysis,
      • 11.3.5.4. Recent developments,
      • 11.3.5.5. strategies,
      • 11.3.5.6. financials (based on availability)
    • 11.3.6. Teva Pharmaceutical Industries Lt
      • 11.3.6.1. Overview,
      • 11.3.6.2. Products,
      • 11.3.6.3. SWOT analysis,
      • 11.3.6.4. Recent developments,
      • 11.3.6.5. strategies,
      • 11.3.6.6. financials (based on availability)
    • 11.3.7. Sanofi
      • 11.3.7.1. Overview,
      • 11.3.7.2. Products,
      • 11.3.7.3. SWOT analysis,
      • 11.3.7.4. Recent developments,
      • 11.3.7.5. strategies,
      • 11.3.7.6. financials (based on availability)
    • 11.3.8. Otsuka Holdings
      • 11.3.8.1. Overview,
      • 11.3.8.2. Products,
      • 11.3.8.3. SWOT analysis,
      • 11.3.8.4. Recent developments,
      • 11.3.8.5. strategies,
      • 11.3.8.6. financials (based on availability)
    • 11.3.9. Other Prominent Players
      • 11.3.9.1. Overview,
      • 11.3.9.2. Products,
      • 11.3.9.3. SWOT analysis,
      • 11.3.9.4. Recent developments,
      • 11.3.9.5. strategies,
      • 11.3.9.6. financials (based on availability)

List of Tables

  • Table 1: Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 2: Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 3: Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 4: Global Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Region, 2025-2034
  • Table 5: North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 6: North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 7: North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 8: North America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country, 2025-2034
  • Table 9: Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 10: Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 11: Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 12: Europe Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 13: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 14: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 15: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 16: Asia Pacific Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 17: Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 18: Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 19: Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 20: Latin America Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034
  • Table 21: Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Class, 2025-2034
  • Table 22: Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Drug Type, 2025-2034
  • Table 23: Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, by Distribution Channel, 2025-2034
  • Table 24: Middle East & Africa Central Nervous System Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2025-2034

List of Figures

  • Figure 1: Global Central Nervous System Treatment Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025 & 2034
  • Figure 3: Global Central Nervous System Treatment Market Forecast (USD billion), by Multiple Sclerosis Drugs, 2025-2034
  • Figure 4: Global Central Nervous System Treatment Market Forecast (USD billion), by Anti-psychotic, 2025-2034
  • Figure 5: Global Central Nervous System Treatment Market Forecast (USD billion), by Anti-epileptic, 2025-2034
  • Figure 6: Global Central Nervous System Treatment Market Forecast (USD billion), by Antidepressants, 2025-2034
  • Figure 7: Global Central Nervous System Treatment Market Forecast (USD billion), by Psychostimulants, 2025-2034
  • Figure 8: Global Central Nervous System Treatment Market Forecast (USD billion), by Narcotic Analgesics, 2025-2034
  • Figure 9: Global Central Nervous System Treatment Market Forecast (USD billion), by Non-Narcotic Analgesics, 2025-2034
  • Figure 10: Global Central Nervous System Treatment Market Forecast (USD billion), by Anaesthetics, 2025-2034
  • Figure 11: Global Central Nervous System Treatment Market Forecast (USD billion), by Antiparkinsons, 2025-2034
  • Figure 12: Global Central Nervous System Treatment Market Forecast (USD billion), by Sedatives, 2025-2034
  • Figure 13: Global Central Nervous System Treatment Market Forecast (USD billion), by General Anaesthesia, 2025-2034
  • Figure 14: Global Central Nervous System Treatment Market Forecast (USD billion), by Other CNS Products, 2025-2034
  • Figure 15: Global Central Nervous System Treatment Market Value Share (%), by Drug Type, 2025 & 2034
  • Figure 16: Global Central Nervous System Treatment Market Value Share (%), by Biologics, 2025 & 2034
  • Figure 17: Global Central Nervous System Treatment Market Value Share (%), by Non-biologics, 2025 & 2034
  • Figure 18: Global Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 19: Global Central Nervous System Treatment Market Forecast (USD billion), by Hospital Pharmacy, 2025-2034
  • Figure 20: Global Central Nervous System Treatment Market Forecast (USD billion), by Retail Pharmacy, 2025-2034
  • Figure 21: Global Central Nervous System Treatment Market Forecast (USD billion), by Others, 2025-2034
  • Figure 22: Global Central Nervous System Treatment Market Value (USD billion), by Region, 2025 & 2034
  • Figure 23: North America Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 24: North America Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 25: North America Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 26: North America Central Nervous System Treatment Market Value Share (%), By Drug Type, 2025
  • Figure 27: North America Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 28: North America Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 29: North America Central Nervous System Treatment Market Value (USD billion), By Country, 2025 & 2034
  • Figure 30: North America Central Nervous System Treatment Market Value Share (%), By Country, 2025
  • Figure 31: Europe Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 32: Europe Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 33: Europe Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 34: Europe Central Nervous System Treatment Market Value Share (%), By Drug Type, 2025
  • Figure 35: Europe Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 36: Europe Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 37: Europe Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 38: Europe Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 39: Asia Pacific Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 40: Asia Pacific Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 41: Asia Pacific Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 42: Asia Pacific Central Nervous System Treatment Market Value Share (%), By Drug Type, 2025
  • Figure 43: Asia Pacific Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Asia Pacific Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Asia Pacific Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Asia Pacific Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Latin America Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 48: Latin America Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 49: Latin America Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 50: Latin America Central Nervous System Treatment Market Value Share (%), By Drug Type, 2025
  • Figure 51: Latin America Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 52: Latin America Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 53: Latin America Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 54: Latin America Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 55: Middle East & Africa Central Nervous System Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 56: Middle East & Africa Central Nervous System Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 57: Middle East & Africa Central Nervous System Treatment Market Value (USD billion), By Drug Type, 2025 & 2034
  • Figure 58: Middle East & Africa Central Nervous System Treatment Market Value Share (%), By Drug Type, 2025
  • Figure 59: Middle East & Africa Central Nervous System Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 60: Middle East & Africa Central Nervous System Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 61: Middle East & Africa Central Nervous System Treatment Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 62: Middle East & Africa Central Nervous System Treatment Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 63: Global Central Nervous System Treatment Market Share (%), By Company, 2025